Clinical Trials Directory

Trials / Completed

CompletedNCT03342521

OFDI-Quantified Intracoronary Thrombus, Antiplatelet Pretreatment Effect and Myocardial Reperfusion

Optical Frequency Domain Imaging-Quantified Intracoronary Thrombus Mass During Primary Percutaneous Coronary Intervention, Its Relationship With Antiplatelet Pretreatment Effect And Its Impact On Myocardial Reperfusion

Status
Completed
Phase
Study type
Observational
Enrollment
63 (actual)
Sponsor
University Hospital, Caen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The management of ST-elevation myocardial infarction in the acute phase requires an optimal antiaggregation combining aspirin and a P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor). Primary percutaneous coronary intervention must be performed within 2 hours of first medical contact. However, even with the new P2Y12 inhibitors, effective platelet inhibition which is required to inhibit the progression of intracoronary thrombus, is present only in half of the patients at 2 hours. Optical coherence tomography (OCT) is the reference method for visualizing and quantifying intracoronary thrombus. The post-stenting intracoronary residual mass evaluated in OCT was associated with altered myocardial reperfusion indices, which were themselves associated with the prognosis of the patient. However, the determinants of this post-stenting residual mass -mostly thrombotic- remain unknown. Measurement of platelet reactivity (expressed as P2Y12 Reaction Unit and Aspirin Reaction Unit) by simple turbidimetric tests (VerifyNow) is available in the cathlab. Enhanced platelet reactivity is reported in patients with acute coronary syndrome and represents a high-risk situation for recurrent coronary events in this setting. The study aims to: 1. to evaluate the relationship between the post-stenting residual intracoronary mass evaluated in OCT and the platelet response at the time of the PCI evaluated by Verify Now 2. to confirm the impact of the residual mass measured by OCT on the EKG and angiographic myocardial reperfusion indices 3. identify patients with high thrombotic risk who may require more intensive antithrombotic therapy 4. identify simple biological markers associated with the residual mass measured by OCT

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESToptical coherence tomography and VerifyNowoptical coherence tomography Imaging P2Y12 and Aspirin reaction units quantification by the VerifyNow

Timeline

Start date
2017-10-13
Primary completion
2018-12-31
Completion
2018-12-31
First posted
2017-11-17
Last updated
2019-04-22

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03342521. Inclusion in this directory is not an endorsement.